Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 200.79

-0.2%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (28932)	6/23/1999 7:44:00 PM
From: bob zagorin	Read Replies (1) of 32384

three stories on raloxifene and henry would you, again, point out LGND's stake in raloxifene. thanks. DRUG TREATS OSTEOPOROSIS AND DECREASES RISK OF BREAST CANCER Postmenopausal women with osteoporosis who were treated with raloxifene hydrochloride for three years lessened their risk of invasive breast cancer by 76 percent. oncology.medscape.com RISK OF INVASIVE BREAST CANCER SUBSTANTIALLY REDUCED IN WOMEN TAKING RALOXIFENE Forty months of data show that raloxifene used to treat osteoporosis in postmenopausal women reduces risk of invasive breast cancer by 76%. oncology.medscape.com TAMOXIFEN USEFUL FOR BREAST CANCER RISK REDUCTION; JURY STILL OUT ON RALOXIFENE While there are adequate data to support a role for tamoxifen in reducing the risk of breast cancer, it is premature to make such a recommendation for raloxifene. oncology.medscape.com Read it Here

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next